New Pathway Identified to Overcome Glioblastoma Chemotherapy Resistance

Researchers at Virginia Tech discover PI3K-beta as a key target to enhance the efficacy of temozolomide in treating glioblastoma.

Glioblastoma treatment has remained unchanged for 50 years, relying on surgery, radiation, and temozolomide.
Temozolomide often loses effectiveness as glioblastoma cells develop resistance.
Virginia Tech scientists identified PI3K-beta as crucial for glioblastoma cell survival during chemotherapy.
Blocking PI3K-beta increases tumor sensitivity to temozolomide, offering a new therapeutic approach.
Future research aims to overcome the blood-brain barrier to deliver PI3K-beta inhibitors effectively.